Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
György Nagy, Nadia M T Roodenrijs, Paco M J Welsing, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 1, pp. 20-33
Open Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 3-18
Open Access | Times Cited: 1015
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 19-34
Open Access | Times Cited: 499
Rheumatoid arthritis
Andrea Di Matteo, Joan M. Bathon, Paul Emery
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2019-2033
Closed Access | Times Cited: 203
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment
Di Wu, Yehao Luo, Tong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99
Therapeutic advances in rheumatoid arthritis
Philip M. Brown, Arthur G. Pratt, Kimme L Hyrich
BMJ (2024), pp. e070856-e070856
Open Access | Times Cited: 67
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Tommaso Lorenzo Parigi, Ferdinando D’Amico, María T. Abreu, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 853-859
Closed Access | Times Cited: 43
Current pharmacological therapy for rheumatoid arthritis, factors for its effectiveness and associated complications: systematic review
Jonathan Rocha
Interdisciplinary Rehabilitation / Rehabilitacion Interdisciplinaria (2024) Vol. 4, pp. 76-76
Open Access | Times Cited: 17
Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis
Yujing Li, Sujun Li, Xiaojuan Zhao, et al.
Cell Research (2025)
Open Access | Times Cited: 1
Epidemiology of rheumatoid arthritis: genetic and environmental influences
Aliki I. Venetsanopoulou, Yannis Alamanos, Paraskevi V. Voulgari, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 9, pp. 923-931
Closed Access | Times Cited: 64
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Sae Ochi, Koshiro Sonomoto, Shingo Nakayamada, et al.
Arthritis Research & Therapy (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 54
Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
Tamás Németh, György Nagy, Thomas Pap
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 8, pp. 1055-1064
Open Access | Times Cited: 46
'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
Yvonne Tan, Maya H Buch
RMD Open (2022) Vol. 8, Iss. 2, pp. e002387-e002387
Open Access | Times Cited: 45
Real-world usage of digital health applications (DiGA) in rheumatology: results from a German patient survey
Hannah Labinsky, Latika Gupta, Maria Gabriella Raimondo, et al.
Rheumatology International (2022) Vol. 43, Iss. 4, pp. 713-719
Open Access | Times Cited: 39
Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study
Yu Cao, Ying Yang, Qingfeng Hu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 35
Residual pain in rheumatoid arthritis: Is it a real problem?
Piercarlo Sarzi‐Puttini, Margherita Zen, F. Arru, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 11, pp. 103423-103423
Closed Access | Times Cited: 26
The role of dendritic cells and their immunometabolism in rheumatoid arthritis
Yuichi Suwa, Yasuo Nagafuchi, Saeko Yamada, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
Osteoclast differentiation in rheumatoid arthritis
Kazuhiro Yokota
Immunological Medicine (2023) Vol. 47, Iss. 1, pp. 6-11
Open Access | Times Cited: 23
Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial
M. Teuwen, Salima van Weely, T. P. M. Vliet Vlieland, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 4, pp. 437-445
Open Access | Times Cited: 9
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
Clementina López‐Medina, Jerusalem Calvo‐Gutiérrez, M. C. Ábalos‐Aguilera, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003975-e003975
Open Access | Times Cited: 7
Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search
Nadia M T Roodenrijs, Paco M J Welsing, Joël van Roon, et al.
Lara D. Veeken (2022) Vol. 61, Iss. 9, pp. 3552-3566
Open Access | Times Cited: 36
Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
Ryu Watanabe, Tadashi Okano, Takaho Gon, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 34
Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?
Mrinalini Dey, György M. Nagy, Elena Nikiphorou
Lara D. Veeken (2022) Vol. 62, Iss. 5, pp. 1773-1779
Open Access | Times Cited: 29
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
Bente Glintborg, Daniela Di Giuseppe, Johan K. Wallman, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 6, pp. 820-828
Open Access | Times Cited: 17
Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
Leticia León, Alfredo Madrid-García, Patricia Lopez-Viejo, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002842-e002842
Open Access | Times Cited: 16
Characteristics of difficult-to-treat axial spondyloarthritis: Results of a real-world multicentric study
Cécile Philippoteaux, Thibaut Delépine, Émeline Cailliau, et al.
Joint Bone Spine (2023) Vol. 91, Iss. 2, pp. 105670-105670
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top